MetaADEDB 2.0 @ LMMD
Ticlopidine
(MTKNGOHFNXIVOS-UHFFFAOYSA-N)
Structure
SMILES
Clc1ccccc1CN1CCc2c(C1)ccs2.Cl
Molecular Formula:
C14H15Cl2NS
Molecular Weight:
300.247
Log P:
4.6997
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
1
TPSA:
31.48
CAS Number(s):
53885-35-1
Synonym(s)
1.
Ticlopidine
2.
53-32C
3.
Ticlid
4.
Ticlodix
5.
Ticlodone
6.
Ticlopidine Hydrochloride
7.
53 32C
8.
5332C
9.
Hydrochloride, Ticlopidine
External Link(s)
MeSHD013988
PubChem Compound11301025
65335
657310
ChEBI9589
CHEMBLCHEMBL1717
KEGGdr:D01028
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NeutropeniaFAERS: 8US FAERS
2ThrombocytopeniaFAERS: 6US FAERS
3HepatotoxicityFAERS: 5US FAERS
4LeukopeniaFAERS: 5US FAERS
5AstheniaFAERS: 4US FAERS
6HypersensitivityFAERS: 4US FAERS
7HypogeusiaFAERS: 4US FAERS
8NauseaFAERS: 4US FAERS
9PancytopeniaFAERS: 4US FAERS
10Toxic Epidermal NecrolysisFAERS: 4US FAERS
11VomitingFAERS: 4US FAERS
12jaundiceFAERS: 4US FAERS
13Abdominal PainFAERS: 3US FAERS
14Arterial thrombosisFAERS: 3US FAERS
15ChillsFAERS: 3US FAERS
16Chromosomal mutationFAERS: 3US FAERS
17Lung infection pseudomonalFAERS: 3US FAERS
18Lupus-like syndromeFAERS: 3US FAERS
19Metabolic acidosisFAERS: 3US FAERS
20OverdoseFAERS: 3US FAERS
21Pneumocystis jiroveci pneumoniaFAERS: 3US FAERS
22PneumoniaFAERS: 3US FAERS
23ProteinuriaFAERS: 3US FAERS
24StomatitisFAERS: 3US FAERS
25Thrombocytopenic purpuraFAERS: 3US FAERS
26Weight decreasedFAERS: 3US FAERS
27AgranulocytosisFAERS: 2US FAERS
28Alanine Aminotransferase IncreasedFAERS: 2US FAERS
29ArthralgiaFAERS: 2US FAERS
30Aspartate Aminotransferase IncreasedFAERS: 2US FAERS
31AspergillosisFAERS: 2US FAERS
32Blue Toe SyndromeFAERS: 2US FAERS
33BronchopneumoniaFAERS: 2US FAERS
34Cardiac ArrestFAERS: 2US FAERS
35Cerebral InfarctionFAERS: 2US FAERS
36Chest PainFAERS: 2US FAERS
37CholestasisFAERS: 2US FAERS
38ConjunctivitisFAERS: 2US FAERS
39CyanosisFAERS: 2US FAERS
40DehydrationFAERS: 2US FAERS
41DermatitisFAERS: 2US FAERS
42DisorientationFAERS: 2US FAERS
43DizzinessFAERS: 2US FAERS
44DysarthriaFAERS: 2US FAERS
45DysgeusiaFAERS: 2US FAERS
46Gamma-Glutamyltransferase IncreasedFAERS: 2US FAERS
47HyperkeratosisFAERS: 2US FAERS
48Intentional misuseFAERS: 2US FAERS
49NeuroborreliosisFAERS: 2US FAERS
50PainFAERS: 2US FAERS
51Pericardial effusionFAERS: 2US FAERS
52Pharmaceutical product complaintFAERS: 2US FAERS
53PleurisyFAERS: 2US FAERS
54PresyncopeFAERS: 2US FAERS
55Pulmonary EmbolismFAERS: 2US FAERS
56PurpuraFAERS: 2US FAERS
57Septic ShockFAERS: 2US FAERS
58Tracheal StenosisFAERS: 2US FAERS
59UrticariaFAERS: 2US FAERS
60White blood cell count decreasedFAERS: 2US FAERS
61nervous system disorderFAERS: 2US FAERS
62Abdominal discomfortFAERS: 1US FAERS
63Acute myocardial infarctionFAERS: 1US FAERS
64AgeusiaFAERS: 1US FAERS
65Allergic respiratory symptomFAERS: 1US FAERS
66Aortic RuptureFAERS: 1US FAERS
67Apallic syndromeFAERS: 1US FAERS
68Aphthous StomatitisFAERS: 1US FAERS
69Blood alkaline phosphatase increasedFAERS: 1US FAERS
70Blood bilirubin unconjugated increasedFAERS: 1US FAERS
71Blood glucose increasedFAERS: 1US FAERS
72Blood lactate dehydrogenase increasedFAERS: 1US FAERS
73BradykinesiaFAERS: 1US FAERS
74Cardiac HypertrophyFAERS: 1US FAERS
75Carotid artery occlusionFAERS: 1US FAERS
76CellulitisFAERS: 1US FAERS
77Cerebrovascular accidentFAERS: 1US FAERS
78CholelithiasisFAERS: 1US FAERS
79Coagulation test abnormalFAERS: 1US FAERS
80Coronary Artery DiseaseFAERS: 1US FAERS
81Creatinine renal clearance decreasedFAERS: 1US FAERS
82DementiaFAERS: 1US FAERS
83Diabetes MellitusFAERS: 1US FAERS
84Diffuse alveolar damageFAERS: 1US FAERS
85Disease complicationFAERS: 1US FAERS
86Drug ineffectiveFAERS: 1US FAERS
87Drug resistanceFAERS: 1US FAERS
88DyslaliaFAERS: 1US FAERS
89DysphoniaFAERS: 1US FAERS
90EczemaFAERS: 1US FAERS
91EnteritisFAERS: 1US FAERS
92EosinophiliaFAERS: 1US FAERS
93EpiglottitisFAERS: 1US FAERS
94Erythema MultiformeFAERS: 1US FAERS
95ErythemaFAERS: 1US FAERS
96GastritisFAERS: 1US FAERS
97Gastrointestinal PainFAERS: 1US FAERS
98HaematotoxicityFAERS: 1US FAERS
99HeadacheFAERS: 1US FAERS
100Hepatorenal SyndromeFAERS: 1US FAERS
101Histiocytosis haematophagicFAERS: 1US FAERS
102Hypertensive crisisFAERS: 1US FAERS
103Intracranial AneurysmFAERS: 1US FAERS
104LacerationFAERS: 1US FAERS
105Leukocytoclastic vasculitisFAERS: 1US FAERS
106LeukocytosisFAERS: 1US FAERS
107LymphadenopathyFAERS: 1US FAERS
108MalaiseFAERS: 1US FAERS
109MonocytosisFAERS: 1US FAERS
110MyalgiaFAERS: 1US FAERS
111Neutrophil count decreasedFAERS: 1US FAERS
112PancreatitisFAERS: 1US FAERS
113PapuleFAERS: 1US FAERS
114Pharyngolaryngeal PainFAERS: 1US FAERS
115Platelet aggregation decreasedFAERS: 1US FAERS
116PneumonitisFAERS: 1US FAERS
117Post procedural complicationFAERS: 1US FAERS
118PruritusFAERS: 1US FAERS
119Rash scalyFAERS: 1US FAERS
120Sinus TachycardiaFAERS: 1US FAERS
121SoporFAERS: 1US FAERS
122Stent occlusionFAERS: 1US FAERS
123SyncopeFAERS: 1US FAERS
124TachycardiaFAERS: 1US FAERS
125Therapy non-responderFAERS: 1US FAERS
126ThrombosisFAERS: 1US FAERS
127Urine output increasedFAERS: 1US FAERS
128VasculitisFAERS: 1US FAERS
129Ventricular hypokinesiaFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.